Wird geladen...

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Xu, Tong, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Thompson, Ian Murchie, Cote, Richard J., Vogelzang, Nicholas J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2014
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970171/
https://ncbi.nlm.nih.gov/pubmed/24616308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.7417
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!